Blair William & Co. IL Has $315.72 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Blair William & Co. IL lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 0.1% in the second quarter, according to its most recent filing with the SEC. The firm owned 927,910 shares of the medical technology company’s stock after acquiring an additional 1,332 shares during the period. Stryker makes up about 1.0% of Blair William & Co. IL’s investment portfolio, making the stock its 21st biggest position. Blair William & Co. IL owned 0.24% of Stryker worth $315,721,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in SYK. Burkett Financial Services LLC bought a new position in Stryker during the fourth quarter worth about $25,000. Central Pacific Bank Trust Division acquired a new position in shares of Stryker in the 1st quarter worth approximately $39,000. DSM Capital Partners LLC acquired a new position in shares of Stryker in the 4th quarter worth approximately $34,000. Accent Capital Management LLC bought a new position in shares of Stryker during the 4th quarter worth approximately $60,000. Finally, Sachetta LLC acquired a new stake in Stryker in the 4th quarter valued at $62,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In related news, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the sale, the vice president now owns 10,042 shares in the company, valued at $3,685,213.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the transaction, the chief financial officer now owns 2,852 shares in the company, valued at $949,716. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. The disclosure for this sale can be found here. Insiders have sold 220,068 shares of company stock worth $71,811,372 in the last three months. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. UBS Group increased their price objective on Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. The Goldman Sachs Group started coverage on shares of Stryker in a research report on Thursday, May 30th. They set a “neutral” rating and a $372.00 target price for the company. Needham & Company LLC boosted their price target on shares of Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Piper Sandler reaffirmed an “overweight” rating and set a $380.00 price objective on shares of Stryker in a report on Tuesday, September 10th. Finally, Morgan Stanley lifted their target price on shares of Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $378.58.

Stryker Stock Performance

Shares of NYSE:SYK opened at $364.00 on Wednesday. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $374.63. The stock has a market capitalization of $138.71 billion, a P/E ratio of 41.55, a P/E/G ratio of 2.87 and a beta of 0.91. The business has a 50-day moving average price of $343.60 and a two-hundred day moving average price of $342.61.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. During the same quarter in the previous year, the company earned $2.54 EPS. Stryker’s revenue was up 8.5% on a year-over-year basis. Equities analysts predict that Stryker Co. will post 12 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.53%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.